Neuphoria Therapeutics Inc. Ordinary Shares NEUP 深 沪
已收盘 09-12 16:00:00 美东时间
13.01
-0.980
-7.01%
华盛通- 最 高14.00
- 今 开14.00
- 成交量 6.75万股
- 最 低 12.74
- 昨 收 13.99
- 总市值 2445.88万
- 52周最高 15.14
- 市盈率 静 --
- 换手率 3.59%
- 52周最低 2.90
- 委 比 -43.27%
- 总股本 188.00万
- 历史最高 15.14
- 量 比 1.00
- 振 幅 9.01%
- 历史最低 2.90
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SLING TV UNVEILS "STREAM TEAM" LINEUP: 10 COLLEGE FOOTBALL PLAYERS SIGNED TO $4.99 NIL DEALS
Sling's new $4.99 Day Pass fuels a first-of-its-kind NIL movement proving streaming value beats streaming hype ENGLEWOOD, Colo., Sept. 12, 2025 /PRNewswire/ -- Sling TV, the most flexible li...
09-12 18:00
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35
Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.
09-11 22:30
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
Neuphoria Therapeutics announced the achievement of 332 participants in the AFFIRM-1 Phase 3 trial for BNC-210, a breakthrough acute treatment for social anxiety disorder (SAD). BNC-210, designed to rapidly alleviate anxiety without sedation or cognitive impairment, has received FDA Fast Track designation. The trial evaluates its safety and efficacy through a public speaking challenge and uses multiple metrics to measure anxiety reduction. With t...
09-04 11:00
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. announced that its CEO, Spyros Papapetropoulos, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The presentation will be available online starting September 5. Neuphoria, a clinical-stage biotech company, is developing therapies for neuropsychiatric disorders, including its lead drug candidate, BNC-210, for the treatment of social anxiety disorder and P...
08-28 20:05
HC Wainwright & Co. Reiterates Buy on Neuphoria Therapeutics, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and maintains $21 price target.
08-26 22:39
ARLO UNVEILS ALL-NEW LINEUP OF SMART HOME SECURITY SOLUTIONS WITH ADVANCED AI-POWERED ARLO INTELLIGENCE
Full range includes new Pan Tilt cameras for both indoor and outdoor use and all-new Pro and Ultra Series models with up to 4K HDR resolution CARLSBAD, Calif., Aug. 26, 2025 /PRNewswire/ -- ...
08-26 20:02
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) announced an upcoming oral presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting. The presentation, titled "Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD Study," will be delivered by Spyros Papapetropoulos, M.D., Ph.D., the Company's President and CEO. The session will take place on W...
05-27 20:10
Neuphoria Therapeutics Q1 EPS $6.55 Up From $(2.83) YoY, Sales $15.00M
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly earnings of $6.55 per share. This is a 331.45 percent increase over losses of $(2.83) per share from the same period last year. The company reported $15.00 million
05-21 04:27
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the fi...
05-02 04:01
